Русский
Experience of treatment of renal anemia in patients on hemodialysis using epoetin alfa (Eralfon). Evaluation of the efficacy of therapy and comparison with foreign practice
DOI: https://dx.doi.org/10.18565/nephrology.2018.3.47-51
E.V. Shutov, O.N. Kotenko, A.V. Pushkina, S.V. Lashutin, P.Kh. Elembaeva
1 SBHCI "City Clinical Hospital n.a. S.P. Botkin of the Moscow Healthcare Department"; Moscow, Russia; 2 FSBEI FPE "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federation; Moscow, Russia; 3 SBHCI "City Clinical Hospital № 52 of the Moscow Healthcare Department"; Moscow, Russia; 4 OOO Fesfarm, Moscow, Russia; 5 FSAEI HE "Peoples' Friendship University of Russia"; Moscow, Russia
Material and methods. The study consisted of two stages. In the beginning, a retrospective study was performed including data of 60 patients who received erythropoietin α in routine practice at the premises of the "Fespharm" Dialysis Center. The purpose of this study was to confirm the hypothesis of small doses of this drug to reach the target Hb level 100–120 g/l. In the subsequent, a prospective study was conducted at the premises of the SBHCI City Clinical Hospital n.a. S.P. Botkin (30 patients) in order to evaluate the effectiveness of the use of erythropoietin α for the treatment of renal anemia with doses of the drug, significantly less than the recommended instructions for the drug, and assessing the factors affecting the effectiveness of treatment.
Conclusion. With the use of erythropoiesis-stimulating agents (ESA), the authors recommend to take into account the body weight of the patient more strictly, in addition to the absolute total weekly dose of the drug. At the same time, the increase in the ESA dose will be faster than the increase in the patient's body weight. The recommended average doses in the instructions to the drug should be determined taking into account the national characteristics of the population, using preparations with different dosage, be more cautious about the appointment of iron preparations, more focusing on transferrin saturation with iron.
About the Autors
Shutov E.V. – Doctor of Medical Sciences, Head of the Department of Nephrology № 12 SBHCI "CCH n.a. S.P. Botkin of Moscow Healthcare Department", Professor at the Department of Nephrology and Hemodialysis, FSBEI FPE RMACPE; Moscow, Russia. E-mail: shutov_e_v@mail.ru
Kotenko O.N. – PhD in Medical Science, Chief External Expert-Nephrologist of the roscientist of the Moscow Healthcare Department, Deputy Chief Physician for Nephrology of the SBHCI "CCH № 52 of Moscow Healthcare Department", Associate Professor at the Department of Hospital Therapy with the Course of Hematology FSAEI HE PFUR; Moscow, Russia.
E-mail: olkotenko@yandex.ru
Pushkina A.V. – PhD in Medical Sciences, Chief Physician of OOO "Fespharm"; Moscow, Russia.
Lashutin S.V. – Nephrologist at the SBHCI "CCH n.a. S.P. Botkin of Moscow Healthcare Department"; Moscow, Russia.
Elembaeva P.Kh. – Nephrologist at the SBHCI "CCH n.a. S.P. Botkin of Moscow Healthcare Department"; Moscow, Russia.
